PRIME MEDICINE
Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.
PRIME MEDICINE
Industry:
Biotechnology Genetics Life Science Medical
Founded:
2019-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.primemedicine.com
Total Employee:
101+
Status:
Active
Total Funding:
385 M USD
Technology used in webpage:
Domain Not Resolving HSTS DNSSEC JQuery CDN Microsoft COVID-19 Microsoft Azure Mobile Optimized Drupal Microsoft Azure US East Region
Similar Organizations
Apogee Therapeutics
Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Cellanome
Cellanome is an integrative multi-omics platform that measures biology through its multi-omics platform.
Colossal Biosciences
Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Inceptive
Inceptive Designs RNA molecules using large-scale deep learning in a tight loop with high-throughput experiments.
MiLaboratories
MiLaboratories is a biotech company developing proprietary software to profile a person's immune picture on a DNA level.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Ann L. Lee Chief Technical Officer @ Prime Medicine
Chief Technical Officer
2021-09-01
Jeremy Duffield Chief Scientific Officer @ Prime Medicine
Chief Scientific Officer
2020-12-01
Allan Reine Chief Financial Officer @ Prime Medicine
Chief Financial Officer
2024-01-01
Keith M. Gottesdiener President & Chief Executive Office @ Prime Medicine
President & Chief Executive Office
2020-07-01
Andrew Anzalone Co-founder @ Prime Medicine
Co-founder
2020-01-01
Founder
Stock Details
Investors List
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Corporate Round - Prime Medicine
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Funding Round - Prime Medicine
Casdin Capital
Casdin Capital investment in Series B - Prime Medicine
T. Rowe Price
T. Rowe Price investment in Series B - Prime Medicine
Arrive
Arrive investment in Series B - Prime Medicine
F-Prime Capital
F-Prime Capital investment in Series B - Prime Medicine
Moore Strategic Ventures
Moore Strategic Ventures investment in Series B - Prime Medicine
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Prime Medicine
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Prime Medicine
Samsara BioCapital
Samsara BioCapital investment in Series B - Prime Medicine
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-05 | Prime Medicine appoints Allan Reine as CFO |
| 2021-10-13 | Prime Medicine Appoints Ann L. Lee as Chief Technical Officer |
Official Site Inspections
http://www.primemedicine.com Semrush global rank: 2.77 M Semrush visits lastest month: 6.65 K
- Host name: 247.154.196.104.bc.googleusercontent.com
- IP address: 104.196.154.247
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Prime Medicine"
Prime Medicine | Delivering on the promise of Prime …
Prime Medicine™ was founded with a goal of transforming the lives of patients with debilitating diseases through the application of our groundbreaking Prime Editing platform and technology.See details»
Patients & Caregivers | Prime Medicine
Current clinical trials. Clinical trials are designed to help determine whether an investigational therapy or treatment is safe and effective. We are currently enrolling patients in Prime-0101, a …See details»
Prime Medicine - Crunchbase Company Profile
Contact Email info@primemedicine.com Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene …See details»
PRME - Prime Medicine, Inc. | Company Profile | OTC Markets
Mar 14, 2025 primemedicine.com (617) 564-0013. Business Description "Prime Medicine is a biotechnology company committed to delivering a new class of differentiated one-time curative …See details»
News Release Details - investors.primemedicine.com
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one …See details»
Prime Medicine, Inc. - Drug pipelines, Patents, Clinical trials
Explore Prime Medicine, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 96 news, and 9 literature, Disease Domain:Nervous System Diseases, …See details»
Prime Medicine - The Org
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing …See details»
Prime Medicine Launches with $315 Million Financing to Deliver …
Prime Medicine envisions a world where Prime Editing can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients and shaping the future of gene editing. …See details»
Prime Medicine, Inc. | Insights
Jan 21, 2025 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Pipeline - Prime Medicine
Learn more about Prime-0101 here, visit clinicaltrials.gov or email us at cgdtrial@primemedicine.com for more information. About PM359. PM359, Prime Medicine’s …See details»
Prime Medicine - Overview, News & Similar companies - ZoomInfo
May 30, 2024 Prime Medicine to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a …See details»
Prime Medicine CEO and Key Executive Team | Craft.co
Prime Medicine's President and CEO, Director is Keith Gottesdiener. Other executives include Jeremy Duffield, CSO; Ann Lee, CTO and 14 others. See the full leadership team at Craft.See details»
News Release Details - investors.primemedicine.com
Mar 18, 2025 -- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages …See details»
Prime Medicine Appoints Three New Directors to its Board of …
Cambridge, Mass., August 11, 2022 – Prime Medicine, Inc. (“Prime Medicine”), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic …See details»
Prime Medicine to Present at Upcoming Investor Conferences
Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one …See details»
Gene-editing firm Prime Medicine files $140m public offer
Feb 15, 2024 Gene-editing biotech Prime Medicine has priced a follow-on public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders.See details»
Media | Prime Medicine
7_13_21 The Boston Globe Startup Prime Medicine emerges with $315m to pioneer a new type of gene editing. The Cambridge company was founded by David Liu, a researcher at the Broad …See details»
Prime Healthcare - Wikipedia
Prime Healthcare Services began in 1985 when Prem Reddy founded Desert Valley Medical Group in Victorville, California. [3] In 1992, Reddy established Primecare Medical Group, and …See details»
Prime Medicine Launches with $315 Million Financing to Deliver …
Jul 13, 2021 For more information, visit www.primemedicine.com or LinkedIn. Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 [email protected] Media …See details»
News Release Details - investors.primemedicine.com
Sep 30, 2024 Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and …See details»